NCT00486421View on ClinicalTrials.gov

Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

November 30, 2008

Conditions
Nonneoplastic Condition
Interventions
BIOLOGICAL

Rituximab

375mg/m2 IV weekly times 4 (days 1, 8, 15, 22)

DRUG

Prednisone

1mg/kg/d PO, taper to off by 8 weeks

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER